Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

NCT07368803 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yifan Wang

Collaborators